|
FY2025
12 months to Aug 31, 2025
|
FY2024
12 months to Aug 31, 2024
|
FY2023
12 months to Aug 31, 2023
|
FY2022
12 months to Aug 31, 2022
|
FY2021
12 months to Aug 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Loss from discontinued operations | |||||
| Loss from continuing operations | |||||
| Adjustments to reconcile net loss to net cash flows used in operating activities: | |||||
| Depreciation | |||||
| Stock based compensation expense | |||||
| Impairment of assets | |||||
| Loss on discontinued operations | |||||
| Changes in operating assets and liabilities: | |||||
| Deferred research and development costs | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable and accrued expenses | |||||
| Related party payable | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Purchase of short-term investments | |||||
| Redemption of short-term investments | |||||
| Capital expenditures | |||||
| Net cash provided by investing activities | |||||
| Proceeds from the issuance of equity securities, net | |||||
| Net cash from financing activities | |||||
| Effect of exchange rate changes on cash and cash equivalents | |||||
| Net increase in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of year | |||||
| Cash and cash equivalents at end of year | |||||
Loading...